attomol^® Factor II 20210G>A Quicktype

The assay attomol^® Factor II 20210G>A Quicktype is used for the supportive diagnosis of thrombophilia. This test can be used to determine the transition 20210G>A in the human factor II gene (prothrombin mutation, rs1799963). It is a manual, qualitative assay using an allel-specific PCR with integrated probe hybridisation. The evaluation takes place by agarose gel electrophoresis, which can be carried out manually or automatically. The sample material has to be genomic DNA prepared from EDTA or citrate blood.

In the second-last step of the blood coagulation cascade, prothrombin (factor II) is converted into the serine protease thrombin. This converts fibrinogen molecules by splitting the firbrinopeptides A and B into fibrin monomeres, which spontaneously aggregate to fibrin polymers. The replacement of guanine (G) at position 20210 of the prothrombin gene by adenine (A) (factor II [prothrombin] mutation) causes an increase in the prothrombin concentration in the blood plasma and thus promotes the development of thromboembolism [Poort et al., 1996, Blood 88: 3698-3703]. The incidence of this mutation is 1-3 % in the European population. In carriers of the heterozygous mutation in prothrombin gene, the risk of thrombosis in combination with other factors (intake of oral oestrogen-containing contraceptives, surgical operations, pregnancy, increased age, smoking) increases 3 to 5-fold compared with healthy people [Markis et al., 1997, Thromb. Haemost. 78: 1426-1429].

• PCR-H₂O
• PCR-buffer
• Primer Factor II 20210G>A
• instructions for use

You can find more informations about Quicktype-Technology here.